Condition
AS
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 3 (1)
Trial Status
Completed2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07383805Not Yet Recruiting
Expression of Tim-3 on Neutrophils in Ankylosing Spondylitis
NCT04392596Not ApplicableCompletedPrimary
Study of Bone Mineral Density and Trabecular Bone Score in Patients With Ankylosing Spondylitis
NCT02893254Phase 3CompletedPrimary
Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis
Showing all 3 trials